{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:47:47Z","timestamp":1775792867358,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulation who completed the extension study and consented to a follow-up questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the extension study (<jats:italic>N<\/jats:italic>\u2009=\u20091842), adults with migraine were randomized to quarterly or monthly fremanezumab. After completing active treatment, patients answered a survey evaluating patient satisfaction, treatment and dosing preferences, and changes in patient-reported outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 557 patients who could have been contacted upon completing the extension study, 302 consented and 253 completed the survey. The mean (standard deviation) satisfaction rating for fremanezumab was 6.1 (1.4; 1\u2009=\u2009\u201cextremely dissatisfied\u201d to 7\u2009=\u2009\u201cextremely satisfied\u201d). Most patients (175 [69.2%]) preferred quarterly over monthly fremanezumab dosing. Among patients taking antiepileptics (most common class of prior preventive medication;<jats:italic>n<\/jats:italic>\u2009=\u2009130), 91.5% preferred fremanezumab. Patients reported improvements in anxiety (74 [67.9%]), sleep quality (143 [56.5%]), and quality of time spent with others (210 [83.0%]) with fremanezumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, treatment satisfaction with fremanezumab was high, most patients preferred quarterly fremanezumab dosing, and fremanezumab was generally preferred to prior preventive medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02638103\">NCT02638103<\/jats:ext-link>(HALO LTS), registered December 22, 2015.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-020-01177-4","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T13:02:47Z","timestamp":1599224567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1223-1215","authenticated-orcid":false,"given":"Dawn C.","family":"Buse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Ramirez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blaine","family":"Cloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"1177_CR1","unstructured":"Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN et al (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39(2 Suppl 2):S1\u2013S59"},{"issue":"3","key":"1177_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","volume":"47","author":"S Diamond","year":"2007","unstructured":"Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 47(3):355\u2013363","journal-title":"Headache."},{"issue":"1","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10194-009-0179-2","volume":"11","author":"F Antonaci","year":"2010","unstructured":"Antonaci F, Dumitrache C, De Cillis I, Allena M (2010) A review of current European treatment guidelines for migraine. J Headache Pain 11(1):13\u201319","journal-title":"J Headache Pain"},{"key":"1177_CR4","doi-asserted-by":"crossref","unstructured":"American Headache Society (2019) The Amercan Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 59(1):1\u201318","DOI":"10.1111\/head.13496"},{"issue":"9","key":"1177_CR5","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 58(9):1408\u20131426","journal-title":"Headache."},{"issue":"5","key":"1177_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68(5):343\u2013349","journal-title":"Neurology."},{"issue":"1","key":"1177_CR7","first-page":"46","volume":"25","author":"JH Ford","year":"2019","unstructured":"Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK (2019) Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm 25(1):46\u201359","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"1177_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 37(5):470\u2013485","journal-title":"Cephalalgia."},{"issue":"1","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC et al (2018) My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain 19(1):115","journal-title":"J Headache Pain"},{"issue":"4","key":"1177_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 53(4):644\u2013655","journal-title":"Headache."},{"issue":"8","key":"1177_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11940-017-0463-4","volume":"19","author":"AR Tso","year":"2017","unstructured":"Tso AR, Goadsby PJ (2017) Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol 19(8):27","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6","journal-title":"J Headache Pain"},{"issue":"1","key":"1177_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-018-0905-8","volume":"19","author":"L Ohlsson","year":"2018","unstructured":"Ohlsson L, Kronvall E, Stratton J, Edvinsson L (2018) Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain 19(1):66","journal-title":"J Headache Pain"},{"key":"1177_CR14","unstructured":"AJOVY (2020) AJOVY (fremanezumab-vfrm) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; revised 2020. Available from: https:\/\/www.ajovyhcp.com\/globalassets\/ajovy\/ajovy-pi.pdf"},{"key":"1177_CR15","unstructured":"AJOVY\u00ae (2019) AJOVY\u00ae (fremanezumab) [summary of product characteristics]. North Wales, PA: Teva Pharmaceuticals GmbH; 2019"},{"issue":"19","key":"1177_CR16","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 319(19):1999\u20132008","journal-title":"JAMA."},{"issue":"10203","key":"1177_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"issue":"22","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 377(22):2113\u20132122","journal-title":"N Engl J Med."},{"key":"1177_CR19","unstructured":"ClinicalTrials.gov. Efficacy and safety of subcutaneous administration of fremanezumab (TEV-48125) for the preventive treatment of migraine (HALO) 2015 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02638103]."},{"key":"1177_CR20","doi-asserted-by":"crossref","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21(1):76","DOI":"10.1186\/s10194-020-01130-5"},{"issue":"1","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-019-1040-x","volume":"20","author":"L D'Antona","year":"2019","unstructured":"D'Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain 20(1):89","journal-title":"J Headache Pain"},{"issue":"1","key":"1177_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-019-0998-8","volume":"20","author":"R Cowan","year":"2019","unstructured":"Cowan R, Cohen JM, Rosenman E, Iyer R (2019) Physician and patient preferences for dosing options in migraine prevention. J Headache Pain 20(1):50","journal-title":"J Headache Pain"},{"issue":"4","key":"1177_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MF Peres","year":"2007","unstructured":"Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N et al (2007) Patients' preference for migraine preventive therapy. Headache. 47(4):540\u2013545","journal-title":"Headache."},{"key":"1177_CR24","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/PPA.S182563","volume":"12","author":"JH Ford","year":"2018","unstructured":"Ford JH, Foster SA, Stauffer VL, Ruff DD, Aurora SK, Versijpt J (2018) Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. Patient Prefer Adherence 12:2413\u20132424","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"1177_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13498","volume":"59","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Gebben DJ, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S et al (2019) Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 59(5):715\u2013726","journal-title":"Headache."},{"key":"1177_CR26","doi-asserted-by":"crossref","unstructured":"Ning X, Cohen JM, Bennett NL, Yang R. Long-term safety of fremanezumab: results of a 1-year study. Neurology. 2019;92(15 Supplement) P1.10-015","DOI":"10.1212\/WNL.92.15_supplement.P1.10-015"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01177-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T05:38:44Z","timestamp":1723527524000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01177-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01177-4","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The survey, informed consent document, and all other relevant patient materials were approved by a central institutional review board (Quorum). All participating patients provided informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DCB has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Lilly, Promius, and Teva Pharmaceuticals. She is on the editorial board of <i>Current Pain and Headache Reports<\/i>. RPC has received consulting fees and honoraria from Teva Pharmaceuticals, Amgen, Alder, and Lilly. SKG, JMC, VR-C, and RY are employees of Teva Pharmaceuticals. BC had no conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}